Q-omics provides the consensus-scored NEK11 profile across patient tissues and cancer cell-line models. NEK11 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NEK11 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, NEK11 RNA expression shows 19,280 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, THCA, and THYM as cancer lineages where NEK11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NEK11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NEK11 survival associations across molecular data types. NEK11 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NEK11 RNA expression–survival associations across cancer types. High NEK11 expression shows unfavorable associations in LGG and KICH, but favorable associations in KIRC, UVM, BRCA and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NEK11 RNA expression.
This table summarizes NEK11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for NEK11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NEK11 shows lower tumor expression in THCA, KICH, LUSC and UCEC and higher tumor expression in LIHC and CHOL. The THCA box plot shows higher NEK11 RNA expression in normal versus tumor tissue (log2 FC = −1.212, t-test p < 0.001).
This table shows molecular features associated with NEK11 in patient tissues and cancer cell lines. In patient samples, NEK11 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, NEK11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Lymphoma.
